Articles tagged with Ovarian Cancer
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Weill Cornell Medicine has received significant funding for various cancer research projects, including precision medicine and drug target discovery. These initiatives aim to improve patient outcomes for challenging cancers, such as breast cancer and ovarian cancer. The funding supports innovative research approaches, including the stu...
Researchers at MIT have developed a handheld device to collect living cells from specific locations in patient samples, enabling early cancer detection and personalized medicine development. The device uses a microfluidic channel to gently detach living cells from tissue, allowing for targeted sampling and cultivation for diagnostics a...
Researchers at the University of Maryland Baltimore County have identified USP15 as a promising new target for ovarian cancer treatment, which appears to rely on the enzyme for survival, division, and spread. Reducing USP15 levels makes cancer cells more sensitive to chemotherapy drugs, potentially leading to less harm to healthy cells.
Defering bilateral salpingo-oophorectomy beyond age 50 increases risk of ovarian cancer in BRCA carriers. The residual risk of ovarian cancer for older women in good health is considered high enough to warrant preventive surgery.
The RENI-1 study found durable and clinically meaningful outcomes for niraparib maintenance therapy in ovarian cancer patients, with median PFS reaching 36.5 months. Long-term niraparib use was feasible, particularly in patients with BRCA1/2 mutations, and did not adversely affect quality of life.
UCSF scientists have invented a way to treat cancer with teacher cells and tumor pieces, combining immune cells grown in the lab with patient tumor samples. The method uses dendritic cells to train T cells to recognize and destroy cancer cells, offering a promising approach to immunotherapy.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
Researchers discover a subset of clear cell ovarian cancers responsive to immunotherapy, driven by inflammation-related protein IL-17. IL-17 acts directly on cancer cells, creating an immune-permissive tumor microenvironment, enabling prediction of treatment response and contributing to personalized medicine.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
A NIH-funded research project has generated a comprehensive collection of patient-derived tumor models, covering 25 types of cancer from thousands of donor tissues. These models closely match their parental tumors in terms of genetic alterations and gene expression signatures, enabling researchers to explore tumor evolution and diversity.
New research from Memorial Sloan Kettering Cancer Center sheds light on leukemia resistance to promising new drugs and the role of bone hardness in the immune battle against metastasis. A telehealth tobacco treatment program also shows promise in helping cancer patients quit smoking.
Researchers discovered a signaling pathway activated by acidic tumor environments that drives resistance to PARP inhibitors. Blocking the pathway resensitizes tumors, suggesting a potential new therapeutic strategy for overcoming acquired resistance.
The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.
The Association for Molecular Pathology recognizes Dartmouth Health medical director Laura J. Tafe for her exceptional leadership and dedication to the field of molecular diagnostics. She has been a member of the organization since 2007 and has held various positions, including president in 2023.
Rates of diagnosis after emergency admission are even higher among women who are young, old, frail, or live in areas of deprivation, findings indicate. Ovarian cancer is the eighth most common female cancer worldwide, taking over 200,000 lives every year.
Researchers found that targeting PAK1 enhances therapeutic efficacy of PARP inhibitors in ovarian cancer by impairing DNA repair. Combining olaparib with IPA-3, a PAK1 inhibitor, results in increased tumor cell killing and DNA damage accumulation.
MSU scientists have discovered a protein called TPPP3 that helps ovarian cancer cells withstand chemotherapy. Removing this protein restores the drug's effectiveness, suggesting a new approach to overcoming resistance. This breakthrough has implications for improving existing treatments and may lead to new therapeutic strategies.
Dr. Dan Landau receives Lotus Award for research on uncovering immunotherapy targets in ovarian cancer. He aims to develop new therapeutic perspectives using single-cell profiling techniques and identify unusual variants of proteins as potential targets.
Researchers developed a nanowire device that selectively captures cancer-related extracellular vesicles from the blood serum of ovarian cancer patients. The technology uses high-performance zinc oxide nanowires and achieves efficient capture of cancer biomarkers with minimal physical burden on patients.
Rice University has received a $2 million CPRIT award to advance cancer research, including new studies in immunotherapy and ovarian cancer. The funding will support the expansion of the Genetic Design and Engineering Center, which provides a centralized hub for DNA tools used in cancer research.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
Researchers at The Wistar Institute and Temple University have identified a metabolic target that can help overcome chemotherapy resistance in ovarian cancer. Elevated alpha-ketoglutarate activates an enzyme called TMLHE, which drives carnitine production and loosens the DNA-histone complex, allowing cells to access and fix damaged DNA.
Researchers discovered that overproduction of a DNA repair protein creates DNA damage mimicking BRCA mutations, which may respond to targeted treatments. Tumors with high levels of EXO1 protein exhibit characteristics similar to BRCA-mutant cells, suggesting personalized therapies could be effective.
Dr. Sandra Orsulic has received two federal awards totaling nearly $2 million to advance research aimed at improving outcomes for women with ovarian cancer. Her team will examine the body's inflammatory response after surgery and develop AI-powered tools to guide personalized treatment.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
A first-in-human trial demonstrates the potential of implantable cytokine factories for treating ovarian cancer, showing a favorable safety profile and encouraging disease stabilization in patients. The therapy successfully activated key immune cells without expanding regulatory T cells, revealing a promising mechanism of action.
A new study found that a fluid surrounding many ovarian tumors, known as ascites, helps cancer cells survive and spread. Researchers discovered that a decades-old cholesterol drug, bezafibrate, can disrupt this protection by altering fat storage and iron control, making cancer cells more vulnerable to existing treatments.
A new research paper presents a practical diagnostic approach for detecting high-grade serous ovarian carcinoma using a low-cost, portable color sensor device. The method tracks inorganic phosphate generated during nucleic acid amplification, producing a visible green signal that correlates with the amount of amplified DNA.
A national UK study found that nearly half of untested breast and ovarian cancer patients carry a heritable genetic variant increasing cancer risk. The study reveals the potential benefits of efficient genetic testing to identify at-risk individuals and inform targeted follow-up care.
Researchers found that melatonin increased vascularization and reduced apoptosis in ovarian grafts, improving their viability. The study used an absorbable sponge to apply melatonin to autologous ovarian tissue transplants in rats, revealing its potential as a treatment option for fertility preservation in young cancer patients.
A new review highlights the emotional, physical, and financial challenges faced by caregivers of women living with ovarian cancer. Caregivers experience anxiety, depression, grief, and burnout, alongside practical barriers such as financial hardship and limited communication with healthcare providers.
Cancer cases are on the rise among younger adults in England, with a significant increase in bowel and ovarian cancer rates. The study found that excess weight is a key contributor, but it's unlikely to fully explain this trend, as trends in risk factors such as smoking and diet have been stable or improving over the past decade.
A rare case of mucinous ovarian carcinoma was reported in a postmenopausal woman, initially misdiagnosed as a pelvic abscess due to nonspecific symptoms and radiologic features. The diagnosis was confirmed after advanced imaging and tumor marker assessment. Early recognition is crucial for timely diagnosis and effective treatment of th...
The KIR-CAR T cell therapy has shown promising results in a Phase I clinical trial, demonstrating safety and increasing efficacy with higher doses. The treatment targets mesothelin, widely expressed on several solid tumor cancers, and limits side effects through its natural 'on-off' mechanism.
A phase I clinical trial found that QLS5132 demonstrated an objective response rate of 50% and a disease control rate of 94.4% in patients with late-stage, platinum-resistant ovarian cancer. The study also showed a favorable safety profile for the treatment.
Ovarian cancer cells induce adipose tissue dysfunction and ADSC senescence, creating favorable conditions for tumor metastasis. Targeting senescent ADSCs with dasatinib plus quercetin or resveratrol achieves remarkable efficacy in delaying tumor progression and reducing metastases.
Four Ontario-based research teams are receiving funding to develop next-generation cancer therapies with improved efficacy and reduced side effects. The projects focus on breast and ovarian cancers, a hard-to-treat form of leukemia, and a 'master regulator' protein involved in many different cancers.
ISM6200 is a potent, potentially best-in-class preclinical candidate targeting NR3C1 for the treatment of ovarian cancer, Hypercortisolism (Cushing’s Syndrome), and other disorders related to excess cortisol. The molecule demonstrates low DDI risks and higher in vivo efficacy across multiple animal models.
A redesigned endoscope, called CAFE, offers a new way to detect early signs of ovarian cancer by combining high-resolution imaging with gentle cell collection. The device successfully imaged fallopian tube tissue and collected large numbers of epithelial cells, suggesting its potential for earlier disease detection.
A study of over 2,300 North Carolina women with ovarian cancer found that both quick and delayed diagnoses had worse survival rates than those diagnosed in the middle. Considering patient severity may improve outcomes for some symptomatic patients.
A novel method for monitoring on-treatment disease burden in high-grade serous ovarian cancer uses tumor-informed breakpoints-spanning ddPCR, detecting superior sensitivity and specificity compared to real-time PCR. The approach may enable sensitive and specific detection of minimal residual disease and early relapse detection.
Researchers mapped PARP inhibitors' distribution using advanced imaging techniques and patient ovarian tumour samples, revealing that build-up of drugs in lysosomes can trap and release certain drugs over time. This mechanism increases exposure to cancer cells, leading to variable treatment responses.
Researchers at UC San Diego discover a new way to re-educate the immune system to attack ovarian cancer tumors by blocking protein FAK. The study offers hope for developing better treatments by turning the tumor environment from immune-suppressing to immune-activating.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
The novel approach outperforms standard CAR-T cell therapy in preclinical studies using mouse models of glioblastoma and ovarian cancer. Armored CAR-T cells eliminate tumors, reshape the tumor environment, and boost immune-cell activity.
Researchers at Linköping University have developed an AI-boosted electronic nose that can detect ovarian cancer from blood plasma samples with high accuracy. The method uses machine learning to identify patterns specific to the disease, making it a promising tool for early detection and improved survival rates.
A Phase II study presents significant overall survival benefits for women with platinum-resistant ovarian cancer treated with elenagen plus gemcitabine. Longer exposure to elenagen correlates with longer survival after treatment discontinuation, suggesting a fundamentally different therapeutic approach.
Ovarian cancer cells recruit protective mesothelial cells in abdominal fluid to form hybrid cell clusters that resist chemotherapy. These clusters use spike-like structures called invadopodia to invade surrounding tissue. The discovery opens new treatment possibilities and could help doctors monitor disease progression.
A new study confirms that opportunistic salpingectomy (OS), which involves removing fallopian tubes during hysterectomy or tubal ligation, reduces the risk of serous ovarian cancer by nearly 80%. The procedure leaves ovaries intact, preserving hormone production and minimizing side effects.
A study published in JAMA found that salpingectomy significantly lowers the risk of developing tubo-ovarian carcinoma. The procedure, typically performed during unrelated pelvic or abdominal surgery, is now recommended as a preventive measure for eligible women.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Five IIT researchers receive Proof-of-Concept grants to develop innovative health technologies, including a smart microscope and edible pills. These projects aim to tackle cancer, dyslexia, and diagnostics with cutting-edge technologies like quantum computing and near-infrared photonic chips.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers found that ovarian cancer transforms the omentum into an environment that favors tumor spread. The study analyzed tissue samples from 15 patients and created a cell atlas of the omentum in diseased and healthy states.
A new study validates OVCAR3 as a reliable model for high-grade serous ovarian carcinoma, providing insights into disease behavior and potential therapeutic targets. The research also explores the effects of repurposed drugs on ovarian cancer cells, revealing promising results for treatment responses.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Studies show that patients with advanced ovarian and metastatic breast cancer dedicate approximately 7 hours per week to cancer-related tasks. Most participants report performing these tasks daily, impacting their time burden. The use of a mobile app facilitated the collection of detailed time-use data.
Lab studies found that a combination of THC and CBD kills ovarian cancer cells without harming healthy cells. The compounds may prevent metastasis and have minimal toxic effects, making them a promising alternative to current treatments.
Sofetabart mipitecan, a novel ADC targeting folate receptor alpha, shows robust clinical activity in patients with platinum-resistant ovarian cancer. The GOG-3133/ FRAmework-01 phase 3 study aims to expand treatment options for recurrent ovarian cancer and address the need for more effective therapies.